variednews: variednews: Emmes Announces Completion of Third AC...

variednews: variednews: Emmes Announces Completion of Third AC...: variednews: Emmes Announces Completion of Third ACTT Clinical ... : ROCKVILLE, Md., Nov. 29:Emmes today announced that it conducted the ...

variednews: Emmes Announces Completion of Third ACTT Clinical ...

variednews: Emmes Announces Completion of Third ACTT Clinical ...: ROCKVILLE, Md., Nov. 29:Emmes today announced that it conducted the data and statistical analysis for the third iteration of the Adaptiv...

Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19

ROCKVILLE, Md., Nov. 29:Emmes today announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT-3), using its proprietary Advantage eClinical system. The ACTT-3 trial assessed the efficacy and safety of interferon beta-1a plus remdesivir compared to remdesivir alone in hospitalized adults with COVID-19. Preliminary data from prior small studies had suggested a potential benefit of interferon beta-1a, a natural antiviral component of the immune system, for COVID-19 patients. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored a randomized, double-blind, placebo-controlled clinical trial that included 969 participants at 63 hospitals in five countries, including the U.S. to evaluate the combination of interferon beta-1a and remdesivir. The study concluded that the use of both Interferon beta-1a and remdesivir was not superior to remdesivir alone in patients hospitalized with COVID-based pneumonia. The results also indicated that the subgroup of participants receiving high-flow oxygen at randomization had worse outcomes after treatment with interferon beta-1a compared with those who received placebo. Michelle Green, Dr. Mat Makowski and Jennifer Ferreira co-authored a report about the ACTT-3 study that was published online on October 18, 2021, in The Lancet Respiratory Medicine. Green, an Emmes vice president and Emmes' ACTT-3 project manager, said that about 10 percent of the Emmes workforce has participated in the ACTT studies. "Working on this research to address the best ways to treat COVID-19 is a source of great pride for our company," she said. Emmes Chief Executive Officer Dr. Christine Dingivan said, "We have served as a Statistical and Data Coordinating Center for NIAID's Division of Microbiology and Infectious Diseases for more than two decades. Our Emmes team looks forward to continuing as active contributors to building the body of knowledge on COVID-19 treatments and vaccines." About the Research This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201500002C and 75N93021C00012. About Emmes Founded in 1977, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company's clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com.

variednews: variednews: Agena Bioscience® and Manchester Unive...

variednews: variednews: Agena Bioscience® and Manchester Unive...: variednews: Agena Bioscience® and Manchester University Announ... : SAN DIEGO, Nov. 29: Agena Bioscience® (part of Mesa Labs' Clinical...

variednews: Agena Bioscience® and Manchester University Announ...

variednews: Agena Bioscience® and Manchester University Announ...: SAN DIEGO, Nov. 29: Agena Bioscience® (part of Mesa Labs' Clinical Genomics Division), a global provider of genetic testing solutions,...

Agena Bioscience® and Manchester University Announce Partnership to Provide Educational Resources to the Pharmacogenomics Industry

SAN DIEGO, Nov. 29: Agena Bioscience® (part of Mesa Labs' Clinical Genomics Division), a global provider of genetic testing solutions, today announced a partnership with Manchester University (MU) to expand awareness and access to PGx educational resources. MU is a leading institution providing innovative pharmacogenomic (PGx) educational programs within healthcare and laboratory sciences. This partnership will enable Agena Bioscience to promote and offer its customers the established MU PGx programs, including the Graduate Certificate in PGx or Master of Science in PGx degree. Both programs are fully online and delivered by Manchester University faculty. The PGx Graduate Certificate is comprised of five courses aimed at providing in-depth education to enhance the clinical capabilities of health care professionals. The MU Master of Science in PGx program provides unparalleled depth and breadth in pharmacogenomics, covering human genetics, bioinformatics, pharmacokinetics, and more. "Our relationship with Agena stems from the mutual goal of expanding the awareness of pharmacogenetic testing and its importance to the future of precision medicine. We believe that pharmacogenomics will increasingly enable physicians and other clinicians to prescribe the right dose of the right medicine at the right time, which ultimately leads to better healthcare outcomes. Our educational programs are aimed at producing applied scientists with opportunities for careers in the PGx laboratory industry, translational companies, and healthcare systems," stated W. Thomas Smith, Pharm.D., J.D., Dean of Pharmacy and Graduate Life Sciences at Manchester University. "We are thrilled to partner with Agena Bioscience, an industry leader in the PGx space, to offer our programs to a broader audience." Peter Dansky, President of Agena Bioscience, expressed enthusiasm about this development, stating, "As a leading provider of PGx testing tools, we are proud to work with Manchester University to provide unique offerings that address our customers' desire to increase their knowledge and proficiency in pharmacogenomics. This partnership highlights our commitment to improving healthcare through precision medicine." Pharmacogenomics has gained enormous popularity in recent years and is spearheading progress in precision medicine. With this partnership, Agena Bioscience and Manchester University strive to provide additional educational resources to support continued growth in this exciting field. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. About Agena Bioscience Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis and is used globally in diverse clinical diagnostic and research fields such as infectious diseases, cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. Agena received Emergency Use Authorization (EUA) for its MassARRAY SARS-CoV-2 Panel in October 2020. For more information about Agena, visit www.agenabio.com. About Manchester University Manchester University offers more than 70 areas of undergraduate study, three master's programs (accountancy, athletic training, and pharmacogenomics), a professional doctorate in pharmacy, and a dual degree in pharmacy and pharmacogenomics to about 1,400 students from 26 states and 19 countries.

variednews: variednews: Deutsche Kreditbank Deploys Pega's Low...

variednews: variednews: Deutsche Kreditbank Deploys Pega's Low...: variednews: Deutsche Kreditbank Deploys Pega's Low-Code Platfo... : MUNICH, Nov. 29:Pegasystems Inc. (NASDAQ: PEGA), the software comp...